Cargando…

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

PURPOSE: GDC-0810 (ARN-810) is a novel, non-steroidal, orally bioavailable, selective estrogen receptor degrader (SERD) that potentially inhibits ligand-dependent and ligand-independent estrogen receptor (ER)-mediated signaling. METHODS: A phase Ia/Ib/IIa dose escalation, combination treatment with...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bardia, Aditya, Mayer, Ingrid, Winer, Eric, Linden, Hannah M., Ma, Cynthia X., Parker, Barbara A., Bellet, Meritxell, Arteaga, Carlos L., Cheeti, Sravanthi, Gates, Mary, Chang, Ching-Wei, Fredrickson, Jill, Spoerke, Jill M., Moore, Heather M., Giltnane, Jennifer, Friedman, Lori S., Chow Maneval, Edna, Chan, Iris, Jhaveri, Komal
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	Clinical Trial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9823088/ https://www.ncbi.nlm.nih.gov/pubmed/36401732 http://dx.doi.org/10.1007/s10549-022-06797-9

Ejemplares similares

Application of a Novel ‘Make and Test in Parallel’ Strategy to Investigate the Effect of Formulation on the Pharmacokinetics of GDC-0810 in Healthy Subjects
por: Cheeti, Sravanthi, et al.
Publicado: (2018)

An Open-label Phase I Study of GDC-0927 in Postmenopausal Women with Locally Advanced or Metastatic Estrogen Receptor–Positive Breast Cancer
por: Chandarlapaty, Sarat, et al.
Publicado: (2023)

The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
por: Joseph, James D, et al.
Publicado: (2016)

Correction: The selective estrogen receptor downregulator GDC-0810 is efficacious in diverse models of ER+ breast cancer
por: Joseph, James D, et al.
Publicado: (2019)

The ERα coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium
por: Rokicki, Jerzy, et al.
Publicado: (2010)

A phase Ib study of pictilisib (GDC-0941) in combination with paclitaxel, with and without bevacizumab or trastuzumab, and with letrozole in advanced breast cancer
por: Schöffski, Patrick, et al.
Publicado: (2018)

Arne
por: Björnson, Björnstjerne, 1832-1910
Publicado: (1959)

Expression of PAM50 Genes in Lung Cancer: Evidence that Interactions between Hormone Receptors and HER2/HER3 Contribute to Poor Outcome()()
por: Siegfried, Jill M., et al.
Publicado: (2015)

HER kinase inhibition in patients with HER2- and HER3-mutant cancers
por: Hyman, David M., et al.
Publicado: (2018)

TRLS-03. PHASE II TRIAL OF GDC-0084 IN COMBINATION WITH TRASTUZUMAB FOR PATIENTS WITH HER2-POSITIVE BREAST CANCER BRAIN METASTASES (BCBM)
por: Leone, Jose Pablo, et al.
Publicado: (2019)

Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors
por: Sonar, Priyanka, et al.
Publicado: (2022)

GDC respond to crisis
Publicado: (2020)

Mentoring, performance and the GDC
por: Saw, Mabel, et al.
Publicado: (2021)

Purification and Characterization of Catalase from Marine Bacterium Acinetobacter sp. YS0810
por: Fu, Xinhua, et al.
Publicado: (2014)

Recombinant Cpn 0810 stimulates proinflammatory cytokine expression and apoptosis in human monocytes
por: CHEN, YUYU, et al.
Publicado: (2015)

Protein secretion in human mammary epithelial cells following HER1 receptor activation: influence of HER2 and HER3 expression
por: Zhang, Yi, et al.
Publicado: (2011)

Quantification of HER family receptors in breast cancer
por: Nuciforo, Paolo, et al.
Publicado: (2015)

Molecular imaging of HER2 receptor: Targeting HER2 for imaging and therapy in nuclear medicine
por: Miladinova, Daniela
Publicado: (2023)

A Phase 1 study of GDC‐0134, a dual leucine zipper kinase inhibitor, in ALS
por: Katz, Jonathan S., et al.
Publicado: (2022)

Arne Jacobsen
por: Jacobsen, Arne

Estrogen Receptor, Progesterone Receptor, and HER2 Receptor Markers in Endometrial Cancer
por: Wang, Caifeng, et al.
Publicado: (2020)

GDC announces new chair
Publicado: (2021)

Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
por: Brand, Toni M., et al.
Publicado: (2013)

Biased activation of the receptor tyrosine kinase HER2
por: Catapano, Claudia, et al.
Publicado: (2023)

Retraction: Mapping C-Terminal Transactivation Domains of the Nuclear HER Family Receptor Tyrosine Kinase HER3
Publicado: (2022)

Mouse models and anti-HER2 therapies
por: Hanker, Ariella B., et al.
Publicado: (2013)

Estrogen Receptor, Progesterone Receptor, and HER-2 Expression in Recurrent Pleomorphic Adenoma
por: de Souza, Ana Amélia, et al.
Publicado: (2019)

The Phosphatase PP2A Interacts With ArnA and ArnB to Regulate the Oligomeric State and the Stability of the ArnA/B Complex
por: Ye, Xing, et al.
Publicado: (2020)

Steroid receptor coactivators, HER-2 and HER-3 expression is stimulated by tamoxifen treatment in DMBA-induced breast cancer
por: Moi, Line L Haugan, et al.
Publicado: (2012)

The prognostic value of Her4 receptor isoform expression in triple-negative and Her2 positive breast cancer patients
por: Machleidt, Anna, et al.
Publicado: (2013)

Updated results and correlative FDG-PET analysis of a phase IB study of vemurafenib and cobimetinib (MEK inhibitor [GDC-0973]), in advanced BRAF(V600)- mutated melanoma (BRIM7)
por: Puzanov, Igor, et al.
Publicado: (2014)

Corrigendum: The Phosphatase PP2A Interacts With ArnA and ArnB to Regulate the Oligomeric State and the Stability of the ArnA/B Complex
por: Ye, Xing, et al.
Publicado: (2020)

Editorial: Cancer Treatment and Early Detection Targeting HER Receptors
por: Cai, Xiaoqing, et al.
Publicado: (2022)

Palbociclib Rechallenge for Hormone Receptor–Positive/HER-Negative Advanced Breast Cancer: Findings from the Phase II BioPER Trial
por: Albanell, Joan, et al.
Publicado: (2023)

Oral metronomic vinorelbine combined with endocrine therapy in hormone receptor-positive HER2-negative breast cancer: SOLTI-1501 VENTANA window of opportunity trial
por: Adamo, Barbara, et al.
Publicado: (2019)

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer
por: Pegram, Mark, et al.
Publicado: (2023)

Arne Jacobsen : obras y proyectos = works and projects
por: Solaguren-Beascoa de Corral, Félix
Publicado: (1989)

HER Family Receptors are Important Theranostic Biomarkers for Cervical Cancer: Blocking Glucose Metabolism Enhances the Therapeutic Effect of HER Inhibitors
por: Martinho, Olga, et al.
Publicado: (2017)

Domain-level epitope mapping of polyclonal antibodies against HER-1 and HER-2 receptors using phage display technology
por: Pérez-Martínez, Dayana, et al.
Publicado: (2022)

Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients
por: Sassen, Andrea, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_c5r7lapl2ivomnj2qis9tj037d